Cipla has announced the formation of a strategic joint venture with Kemwell Biopharma, marking a significant expansion into the biologics segment. The partnership will focus on creating and marketing biologic products through a structured collaboration.

Joint Venture Structure

The companies have established a 60:40 partnership arrangement, with specific details outlined below:

Strategic Partnership Details

Both partners will contribute up to 100 million rupees to support the joint venture's operations and development activities. This investment commitment demonstrates the companies' dedication to establishing a strong presence in the biologics market.

The collaboration brings together Cipla's established pharmaceutical market presence with Kemwell Biopharma's specialized expertise in biologics development and manufacturing. The partnership is structured to leverage the complementary strengths of both organizations.

Business Objectives

The joint venture will focus on the creation and marketing of biologic products, representing an important strategic move for both companies. This collaboration positions the partners to capitalize on the growing biologics market segment through their combined capabilities and resources.

The 60:40 ownership structure provides a clear framework for decision-making and resource allocation within the partnership, ensuring effective governance of the joint venture operations.

Cipla Limited has announced the incorporation of a new wholly owned subsidiary in the Kingdom of Saudi Arabia, marking a strategic expansion into the Middle Eastern pharmaceutical market. The company informed stock exchanges on 2nd March, 2026, about the establishment of 'Cipla Middle East Company' effective 1st March, 2026.

Subsidiary Structure and Incorporation Details

The new subsidiary was incorporated by Cipla (EU) Limited, UK, which is itself a wholly owned subsidiary of Cipla Limited. This creates a step-down subsidiary structure for the company's Middle Eastern operations.

Business Objectives and Strategic Purpose

Cipla Middle East Company has been incorporated with specific objectives aligned with the pharmaceutical industry. The subsidiary will focus on:

• Manufacturing pharmaceutical products in Saudi Arabia
• Distribution of pharmaceutical products across the region
• Holding marketing authorizations in the Kingdom of Saudi Arabia

The establishment of this subsidiary represents Cipla's commitment to expanding its presence in the Middle Eastern pharmaceutical market and establishing local manufacturing capabilities.

Regulatory Compliance and Disclosure

The incorporation was disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required by SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026.

Market Expansion Strategy

The incorporation of Cipla Middle East Company demonstrates the company's strategic approach to international expansion. By establishing a local entity in Saudi Arabia, Cipla positions itself to better serve the Middle Eastern pharmaceutical market while maintaining compliance with local regulatory requirements.

As a newly incorporated entity, the subsidiary currently has no applicable turnover or historical financial data. The focus remains on establishing operational capabilities and securing necessary regulatory approvals for pharmaceutical manufacturing and distribution activities in the Kingdom of Saudi Arabia.